Evidence map›Paper›PMID 35999168›Full record

ArticleEuropean urology focus2023

Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice.

Joaquin Mateo, Himisha Beltran

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology focus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Joaquin MateoVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus, Barcelona, Spain.
Himisha BeltranDana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: himisha_beltran@dfci.harvard.edu.
Dana-Farber Cancer Institute · USVall d'Hebron Institute of Oncology

Funding

Molecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1M
NCI NIH HHS R37 CA241486
6 · The paper itself

Abstract

Genomic profiling represents the first clinical practice-ready tool for precision oncology in metastatic prostate cancer. Here we outline current testing considerations and gray zones regarding how best to apply genomic testing in the clinic. The lessons we learn today will continue to shape how we integrate evolving biology and future technologies into practice.

Indexed as

Precision MedicineProstatic NeoplasmsForecastingHumansMaleMedical Oncology

Identifiers

PMID35999168
PMCPMC11832036
OpenAlexW4292414892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.